艾美疫苗(06660)早盘一度涨超6%,截至发稿,股价上涨4.92%,现报6.40港元,成交额1147.95万港元。
12月19日,艾美疫苗发布公告,集团新技术路线悬浮培养四价MDCK细胞流感疫苗,已于近日获得国家药品监督管理局《药物临床试验批准通知书》,标志着该疫苗的研发进入了新的阶段。目前,国内上市的流感疫苗均基于鸡胚工艺生产,尚无基于细胞基质的流感疫苗获批上市。MDCK细胞流感疫苗作为重磅大单品,该款产品上市后有望成为集团新的业绩增长点。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.